N/A
N=40
Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients
Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT02006836 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcome: Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pomelo (Dietary_supplement); Glucose (Dietary_supplement); Blank (Other); Insulin (Drug); met or diet (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Huazhong University of Science and Technology
- Primary completion
- Dec 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glycemic Index |
76.79; 86.92 | 0.005 sig |
| PRIMARY ∆g of Breakfast With/Without Pomelo |
2.93; 3.61 | >0.05 |
| PRIMARY ∆g of Lunch With/Without Pomelo |
1.39; 2.87 | >0.05 |
| PRIMARY ∆g of Dinner With/Without Pomelo |
0.34; 1.41 | >0.05 |
| PRIMARY AUCs With/Without Pomelo |
164.04; 163.07 | >0.05 |
Summary
Food intake has a great influence on blood glucose of patients with diabetes. This study was designed to determine the glycemic index (GI) of a particular pomelo named Majia pomelo and its effects on postprandial glucose (PPG) excursions in both healthy subjects and patients with type 2 diabetes (T2DM).
Eligibility Criteria
Inclusion Criteria
- In the diabetic and diabetic 2 groups, it required that their diabetes was controlled (HbA1c ≤ 8%) on diet with or without metformin.
Exclusion Criteria
- Morbid obesity (BMI > 40 kg/m2)
- Pre diabetes
- Pregnancy
- Presence of gastroenterological disorders
- Alimentary tract surgery
- A history of gastroenteritis in the prior six months
- Any alcohol intake
- Smoking
- Taking any medications (except metformin)
- Poorly controlled diabetes (HbA1c > 8%)
- Presence of chronic diseases (such as bronchial asthma or rheumatoid arthritis) or acute illness (such as upper respiratory tract or urinary tract infection)
Data sourced from ClinicalTrials.gov (NCT02006836). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.